vs
Side-by-side financial comparison of American Assets Trust, Inc. (AAT) and Amphastar Pharmaceuticals, Inc. (AMPH). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $110.6M, roughly 1.7× American Assets Trust, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 6.1%, a 7.2% gap on every dollar of revenue. On growth, American Assets Trust, Inc. posted the faster year-over-year revenue change (1.8% vs -1.8%). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -0.1%).
Personal Assets Trust is a large British investment trust. The company is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index. The chairman is Iain Ferguson CBE.
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
AAT vs AMPH — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $110.6M | $183.1M |
| Net Profit | $6.7M | $24.4M |
| Gross Margin | — | 46.8% |
| Operating Margin | 23.4% | 19.4% |
| Net Margin | 6.1% | 13.3% |
| Revenue YoY | 1.8% | -1.8% |
| Net Profit YoY | -16.3% | -35.7% |
| EPS (diluted) | $0.08 | $0.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $110.6M | — | ||
| Q4 25 | $110.1M | $183.1M | ||
| Q3 25 | $109.6M | $191.8M | ||
| Q2 25 | $107.9M | $174.4M | ||
| Q1 25 | $108.6M | $170.5M | ||
| Q4 24 | $113.5M | $186.5M | ||
| Q3 24 | $122.8M | $191.2M | ||
| Q2 24 | $110.9M | $182.4M |
| Q1 26 | $6.7M | — | ||
| Q4 25 | — | $24.4M | ||
| Q3 25 | $4.5M | $17.4M | ||
| Q2 25 | $5.5M | $31.0M | ||
| Q1 25 | $42.5M | $25.3M | ||
| Q4 24 | — | $38.0M | ||
| Q3 24 | $16.7M | $40.4M | ||
| Q2 24 | $11.9M | $37.9M |
| Q1 26 | — | — | ||
| Q4 25 | 59.4% | 46.8% | ||
| Q3 25 | 60.5% | 51.4% | ||
| Q2 25 | 62.6% | 49.6% | ||
| Q1 25 | 62.0% | 50.0% | ||
| Q4 24 | 61.3% | 46.5% | ||
| Q3 24 | 65.5% | 53.3% | ||
| Q2 24 | 63.6% | 52.2% |
| Q1 26 | 23.4% | — | ||
| Q4 25 | 21.1% | 19.4% | ||
| Q3 25 | 22.6% | 13.2% | ||
| Q2 25 | 24.1% | 24.2% | ||
| Q1 25 | 66.3% | 21.9% | ||
| Q4 24 | 26.5% | 24.2% | ||
| Q3 24 | 30.8% | 29.8% | ||
| Q2 24 | 27.8% | 30.3% |
| Q1 26 | 6.1% | — | ||
| Q4 25 | — | 13.3% | ||
| Q3 25 | 4.1% | 9.0% | ||
| Q2 25 | 5.1% | 17.8% | ||
| Q1 25 | 39.2% | 14.8% | ||
| Q4 24 | — | 20.4% | ||
| Q3 24 | 13.6% | 21.1% | ||
| Q2 24 | 10.7% | 20.8% |
| Q1 26 | $0.08 | — | ||
| Q4 25 | $0.06 | $0.51 | ||
| Q3 25 | $0.07 | $0.37 | ||
| Q2 25 | $0.09 | $0.64 | ||
| Q1 25 | $0.70 | $0.51 | ||
| Q4 24 | $0.14 | $0.74 | ||
| Q3 24 | $0.28 | $0.78 | ||
| Q2 24 | $0.20 | $0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $118.3M | $282.8M |
| Total DebtLower is stronger | — | $608.7M |
| Stockholders' EquityBook value | $1.1B | $788.8M |
| Total Assets | $2.9B | $1.6B |
| Debt / EquityLower = less leverage | — | 0.77× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $118.3M | — | ||
| Q4 25 | $129.4M | $282.8M | ||
| Q3 25 | $138.7M | $276.2M | ||
| Q2 25 | $143.7M | $231.8M | ||
| Q1 25 | $143.9M | $236.9M | ||
| Q4 24 | $425.7M | $221.6M | ||
| Q3 24 | $533.0M | $250.5M | ||
| Q2 24 | $114.9M | $217.8M |
| Q1 26 | — | — | ||
| Q4 25 | $1.7B | $608.7M | ||
| Q3 25 | — | $608.6M | ||
| Q2 25 | — | $607.7M | ||
| Q1 25 | — | $603.9M | ||
| Q4 24 | $2.0B | $601.6M | ||
| Q3 24 | — | $596.4M | ||
| Q2 24 | — | $586.9M |
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.2B | $788.8M | ||
| Q3 25 | $1.2B | $776.7M | ||
| Q2 25 | $1.2B | $757.5M | ||
| Q1 25 | $1.2B | $751.3M | ||
| Q4 24 | $1.2B | $732.3M | ||
| Q3 24 | $1.2B | $727.7M | ||
| Q2 24 | $1.2B | $713.3M |
| Q1 26 | $2.9B | — | ||
| Q4 25 | $2.9B | $1.6B | ||
| Q3 25 | $2.9B | $1.7B | ||
| Q2 25 | $3.0B | $1.6B | ||
| Q1 25 | $3.0B | $1.6B | ||
| Q4 24 | $3.3B | $1.6B | ||
| Q3 24 | $3.4B | $1.5B | ||
| Q2 24 | $3.0B | $1.5B |
| Q1 26 | — | — | ||
| Q4 25 | 1.48× | 0.77× | ||
| Q3 25 | — | 0.78× | ||
| Q2 25 | — | 0.80× | ||
| Q1 25 | — | 0.80× | ||
| Q4 24 | 1.72× | 0.82× | ||
| Q3 24 | — | 0.82× | ||
| Q2 24 | — | 0.82× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $32.9M |
| Free Cash FlowOCF − Capex | — | $24.6M |
| FCF MarginFCF / Revenue | — | 13.4% |
| Capex IntensityCapex / Revenue | 14.5% | 4.5% |
| Cash ConversionOCF / Net Profit | — | 1.35× |
| TTM Free Cash FlowTrailing 4 quarters | — | $121.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $167.1M | $32.9M | ||
| Q3 25 | $40.5M | $52.6M | ||
| Q2 25 | $49.2M | $35.6M | ||
| Q1 25 | $36.9M | $35.1M | ||
| Q4 24 | $207.1M | $29.0M | ||
| Q3 24 | $52.4M | $60.0M | ||
| Q2 24 | $59.3M | $69.1M |
| Q1 26 | — | — | ||
| Q4 25 | $94.9M | $24.6M | ||
| Q3 25 | $23.1M | $47.2M | ||
| Q2 25 | $28.4M | $25.0M | ||
| Q1 25 | $20.4M | $24.4M | ||
| Q4 24 | $136.9M | $16.6M | ||
| Q3 24 | $28.0M | $46.2M | ||
| Q2 24 | $43.6M | $63.1M |
| Q1 26 | — | — | ||
| Q4 25 | 86.2% | 13.4% | ||
| Q3 25 | 21.1% | 24.6% | ||
| Q2 25 | 26.3% | 14.3% | ||
| Q1 25 | 18.8% | 14.3% | ||
| Q4 24 | 120.7% | 8.9% | ||
| Q3 24 | 22.8% | 24.1% | ||
| Q2 24 | 39.3% | 34.6% |
| Q1 26 | 14.5% | — | ||
| Q4 25 | 65.6% | 4.5% | ||
| Q3 25 | 15.9% | 2.8% | ||
| Q2 25 | 19.3% | 6.1% | ||
| Q1 25 | 15.1% | 6.3% | ||
| Q4 24 | 61.9% | 6.7% | ||
| Q3 24 | 19.9% | 7.2% | ||
| Q2 24 | 14.1% | 3.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.35× | ||
| Q3 25 | 8.98× | 3.03× | ||
| Q2 25 | 9.01× | 1.15× | ||
| Q1 25 | 0.87× | 1.39× | ||
| Q4 24 | — | 0.76× | ||
| Q3 24 | 3.15× | 1.48× | ||
| Q2 24 | 4.98× | 1.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AAT
| Rental income | $104.4M | 94% |
| Other | $6.2M | 6% |
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
